WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC	Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder	Recruiting	Phase 2	2025-10-03		NCT04644289

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AGO Research GmbH	3

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Charité Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie	Berlin	Germany	1
KEM Essen \| Evang. Kliniken Essen Mitte	Essen	Germany	1
Klinikum rechts der Isar, Technische Universität München, Klinik und Poliklinik für Frauenheilkunde	München	Germany	1
Mammazentrum HH am Krankenhaus Jerusalem, Gynäkologisches Operationszentrum Hamburg	Hamburg	Germany	1
Universitätsklinikum Carl Gustav Carus Dresden an der technischen Universität Dresden, Gynäkologisches Krebszentrum und Regionales Brustzentrum Dresden am Universitäts-KrebsCentrum	Dresden	Germany	1
Universitätsklinikum Mannheim GmbH, Frauenklinik	Mannheim	Germany	1